Esketamine Nasal Spray versus Quetiapine for Treatment-Resistant Depression.

Andreas ReifIstvan BitterJozefien BuyzeKerstin CebullaRichard FreyDong-Jing FuTetsuro ItoYerkebulan KambarovPierre-Michel LlorcaAlbino J Oliveira-MaiaThomas MesserSiobhán Mulhern-HaugheyBenoît RiveChristian von HoltAllan H YoungYordan Godinovnull null

Published in: The New England journal of medicine (2023)

In patients with treatment-resistant depression, esketamine nasal spray plus an SSRI or SNRI was superior to extended-release quetiapine plus an SSRI or SNRI with respect to remission at week 8. (Funded by Janssen EMEA; ESCAPE-TRD ClinicalTrials.gov number, NCT04338321.).

Keyphrases

depressive symptoms
sleep quality
chronic rhinosinusitis
clinical trial
systemic lupus erythematosus
study protocol